Table 2.
Estimates of NCEP-defined Metabolic Syndrome Prevalence with Bipolar Disorder
| Study | Sample | N (Male/Female) | Prevalence (Male/Female) |
|---|---|---|---|
| Cardenas et al. (69) | Outpatients from a West Los Angeles Veterans Affairs clinic | 98 (90/8) | 49% (49%/50%) |
| Fagiolini et al. (58) | Consecutive recruits from 2003–2004 for bipolar disorder center in PA | 171 (67/104) | 30% (31%/29%) |
| Fiedorowicz et al. (61) | Outpatients from a tertiary care center with primary diagnosis of bipolar disorder | 60–125 (46/79) | 36 – 55% (52–64%/27–46%) |
| Garcia-Portilla et al. (70) | Naturalistic, multicenter, cross- sectional study in Spain | 194 (95/99) | 22.4% a (19%/26%) |
| Teixeira and Rocha (73) | Consecutive sample of psychiatric inpatients | 47 (35/12) | 38.3% b (43%/25%) |
| van Winkel et al. (71) | Pre-screening for patients with bipolar disorder started on antipsychotics. | 60 (34/26) | 16.7% c (19%/15%) |
| Yumru et al. (74) | Young sample of outpatients with bipolar disorder in Turkey | 125 (78/47) | 32% d (30%/36%) |
a
Nearly 60% higher than expected from general Spanish population
b
More than 60% higher than expected from general Brazilian population (< 24%)
c
Double the expected prevalence in Belgium
d
Nearly twice as high as expected prevalence (17.9%) in Turkey